文献速递临床试验与 GCP基础与转化研究

纳米姜黄素补充对冠状动脉慢血流现象患者心血管代谢危险因素、生理与心理生活质量及抑郁的影响:一项随机双盲临床试验

Effect of nano-curcumin supplementation on cardiometabolic risk factors, physical and psychological quality of life, and depression in patients with coronary slow flow phenomenon: a randomized double-blind clinical trial.
PubMed 文献 · Trials · 2024-07-31

该随机双盲安慰剂对照临床试验纳入42例冠状动脉慢血流现象患者,每日给予80毫克纳米姜黄素或安慰剂共12周。结果显示纳米姜黄素组生理与心理生活质量评分显著改善、抑郁程度较轻者数量显著增多,并阻止了血糖控制恶化,但hs-CRP和内脏脂肪素无显著改善。

要点

  • 纳米姜黄素组生理与心理生活质量评分较安慰剂组显著改善。
  • 纳米姜黄素组抑郁程度较轻者数量显著多于安慰剂组。
  • 纳米姜黄素阻止了血糖控制恶化,但hs-CRP和内脏脂肪素无显著改善。

核心结论

  • 姜黄素补充可阻止冠状动脉慢血流现象患者血糖控制恶化,并改善生理与心理生活质量及抑郁。

研究设计与样本

  • 随机双盲安慰剂对照临床试验,纳入42例冠状动脉慢血流现象患者,年龄35-70岁,25≤体重指数<40 kg/m2。
  • 患者每日接受80毫克纳米姜黄素或安慰剂,持续12周。
  • 干预前后测量血清内脏脂肪素、高敏C反应蛋白(hs-CRP)和血糖指标,并评估SF-36生活质量问卷和贝克抑郁量表-II(BDI-II)。

主要发现

  • 安慰剂组较纳米姜黄素组空腹血糖变化显著升高(-0.9±12.2 vs 7.7±12.4 mg/dl,p=0.02)。
  • 安慰剂组较纳米姜黄素组糖化血红蛋白变化显著升高(-0.1±0.8 vs 0.5±0.8%,p=0.04)。
  • 纳米姜黄素组较安慰剂组生理成分汇总评分显著改善(8.2±8.1 vs -1.2±6.5,p<0.001)。
  • 纳米姜黄素组较安慰剂组心理成分汇总评分显著改善(6.8±11.8 vs -1.1±10.4,p=0.02)。
  • 纳米姜黄素组较安慰剂组抑郁程度较轻的患者数量显著更多(p=0.046)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extensive evidence has suggested the cardio-protective properties of the polyphenol curcumin. The aim of this study was to investigate the effects of a highly bioavailable curcumin supplement on cardiometabolic risk factors, health-related quality of life, and depression in patients with coronary slow flow phenomenon (CSFP). METHODS: This randomized double-blind placebo-controlled clinical trial was conducted in 42 patients with CSFP (age 35-70 years, 25 ≤ body mass index < 40 kg/m2). Patients received either 80 mg/day nano-curcumin or placebo for 12 weeks. Serum levels of visfatin, high-sensitivity C-reactive protein (hs-CRP), and glycemic indices were measured before and after the intervention. The short form 36-item quality of life (SF-36) and Beck's Depression Inventory-II (BDI-II) questionnaires were assessed, as well. RESULTS: No significant improvements were observed in circulating hs-CRP and visfatin following the intervention. A significant increase was observed in pre- to post-fasting blood glucose (- 0.9 ± 12.2 vs. 7.7 ± 12.4 mg/dl, p = 0.02) and hemoglobin A1C (- 0.1 ± 0.8 vs. 0.5 ± 0.8%, p = 0.04) levels, in the placebo compared with the intervention group. Physical (8.2 ± 8.1 vs. - 1.2 ± 6.5, p < 0.001) and mental (6.8 ± 11.8 vs. - 1.1 ± 10.4, p = 0.02) component summary scores were significantly improved in the nano-curcumin than the placebo group. Additionally, the number of patients with lower degrees of depression was significantly better in the intervention than the placebo group following the supplementation (p = 0.046). CONCLUSION: Curcumin supplementation prevented deterioration of glycemic control and improved physical and psychological quality of life and depression in patients with CSFP. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT20131125015536N8), June 19, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Soltani M, Hosseinzadeh-Attar MJ, Rezaei M, et al. Effect of nano-curcumin supplementation on cardiometabolic risk factors, physical and psychological quality of life, and depression in patients with coronary slow flow phenomenon: a randomized double-blind clinical trial. Trials. 2024. PMID: 39085864. doi:10.1186/s13063-024-08354-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。